Dizal Reveals New Findings From Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological...

PR NewswireMay 24 04:32 ET

2024 ASCO | Dizhe Pharmaceutical's latest exploratory biomarker analysis adds new data to Schwarzer's treatment of EGFR exon20ins mutant non-small cell lung cancer

Baseline plasma circulating tumor DNA (ctDNA) tests positive and negative epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutations were observed to benefit after receiving Schwarzhe treatment. Schwarzhe directly acts on the EGFR signaling pathway and can effectively remove the EGFR exon20ins mutation in plasma ctDNA. Schwarzell's drug resistance mechanism shows EGFR-dependent and EGFR-independent pathways. Goliximinib (JAK1 inhibitor) combined chemotherapy is a potential solution in Shanghai 2024 May 24

PR NewswireMay 24 04:29 ET

Digger Pharmaceuticals (688192.SH): Schwarzer's latest research results were selected for the 2024 American Society of Clinical Oncology Conference Report

Glonghui, May 24, 丨 Dizhe Pharmaceutical (688192.SH) announced that at the American Society of Clinical Oncology (ASCO) annual meeting to be held in Chicago from May 31 to June 4, 2024, the company will announce the two latest research results of its self-developed novel Class I lung cancer target drug Schwarzhe (generic name: sulvortinib tablets) targeting epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutant advanced non-small cell lung cancer (NSCLC). Among them is Schwarzer? Global Note on Treated EGFrexon20InS Mutant NSCLC

Gelonghui FinanceMay 24 04:04 ET

Downgrade: Here's How Analysts See Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Performing In The Near Term

The latest analyst coverage could presage a bad day for Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192), with the analysts making across-the-board cuts to their statutory estimates that might l

Simply Wall StMay 8 18:37 ET

Dizhe Pharmaceutical (688192.SH): Chairman and others completed an increase in holdings of 6.59 million yuan

Zhitong Finance App News, Dizhe Pharmaceutical (688192.SH) announced that as of May 8, 2024, Dr. Zhang Xiaolin, Chairman and CEO of the company, Mr. Lu Hongbin, Secretary of the Board of Directors and Chief Financial Officer, and Ms. Wu Qingyi, Deputy General Manager and Chief Commercial Officer, have increased their holdings by 1991.88 million shares, accounting for 0.0479% of the company's total share capital, with a total increase of 6.597.42 million yuan. The plan to increase holdings has been completed.

Zhitong FinanceMay 8 05:33 ET

These 4 Measures Indicate That Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor

Simply Wall StApr 30 20:55 ET